# Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/abacavir-dolutegravir-lamivudine

> The FDA approved Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine), sponsored by GSK plc (GSK), on March 30, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine) |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | priority review |

## Timeline

### March 1, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA205551 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20210301, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product TRIUMEQ (ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205551%22

### March 30, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215413 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220330, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TRIUMEQ PD (ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215413%22

### March 30, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA205551 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20220330, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TRIUMEQ (ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205551%22

### June 15, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215413 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20230615, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TRIUMEQ PD (ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215413%22
- openFDA Drugs@FDA: "NDA205551 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20230615, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TRIUMEQ (ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205551%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/abacavir-dolutegravir-lamivudine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/abacavir-dolutegravir-lamivudine

```bibtex
@misc{secapidev_pdufa_abacavir_dolutegravir_lamivudine_20261116,
  title        = {Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/abacavir-dolutegravir-lamivudine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_abacavir_dolutegravir_lamivudine_20261116","title":"Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/abacavir-dolutegravir-lamivudine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
